Receive a complete Daily History of this Stock You can receive a complete daily file of this issue since 1970 or stock inception. We will email you the file in ASCII format within a few hours or ordering. Product Details | Order

Business Description
Gilead Sciences, Inc. is an independent biopharmaceutical company that discovers, develops and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company has five products that are marketed in the United States and in other countries worldwide. These are Viread, a drug for treating HIV infection; AmBisome, a drug for treating and preventing life-threatening fungal infections; Tamiflu, a drug for treating and preventing influenza; Vistide, a drug for treating cytomegalovirus (or CMV) retinitis in AIDS patients, and DaunoXome, a drug for treating AIDS-related Kaposi's sarcoma.

Financial Information
Gilead Sciences, Inc. provide accelerated solutions for patients and caretakers with a focus on developing and marketing drugs to treat patients with infectious diseases. For the six months ended 6/30/02, revenues rose 73% to $187.8 million. Net income before acct. change totaled $15.9 million vs. a loss of $55.2 million. Revenues reflect increased sales of AmBisome. Earnings also reflect improved operating margins and lower research and development expenses.